Friday, December 23, 2016

Primary progressive MS, polyomavirus, CD20, and Orcerlizumab

The reason the new drug ocrelizumab works is because this form of multiple sclerosis was triggered by a polyomavirus cross-targeting with a larger infection (mycobacteria or staph).

Polyomavirus and CD20
https://www.ncbi.nlm.nih.gov/pubmed/11349723

Ocrelizumab is an anti-CD20
https://en.wikipedia.org/wiki/Ocrelizumab

Primary progressive MS : polyomavirus  (hepatitis B, JC, BK) HLA-C
https://healthimpactnews.com/2014/new-study-hepatitis-b-vaccination-in-france-sparked-a-wave-of-new-cases-of-ms/

previous blog post about multiple sclerosis
http://angelabiggs.blogspot.com/2016/11/the-4-types-of-ms-viruses-and-hlas.html

Autoimmune cross-targeting hypothesis:

The layering of 2 different infections on one target cell type triggers autoimmune disease.  A viral infection marking the inside of the target then a bacterial, or fungal, or mycobacteria, or spirochete infection marking the outside.

Note that a vaccine can trigger autoimmune disease by attracting the immune system to the receptor the virus would bind unless that piece is removed from the vaccine.

France and hepatitis B vaccine triggering MS
https://healthimpactnews.com/2014/new-study-hepatitis-b-vaccination-in-france-sparked-a-wave-of-new-cases-of-ms/

virus receptor binding
http://angelabiggs.blogspot.com/2016/12/viruses-and-benzene-rings.html

The infections are not causing the autoimmune disease it is the immune system which is uncoupled with a cross-targeting issue.  Both the T cells and the B cells self educations cannot be turned off at the same time. 

No comments:

Post a Comment